In clinical NSCLC samples, PD-L1 expression was significantly increased in the cisplatin-resistant group, and PD-L1 expression was positively correlated with c-Jun expression but negatively correlated with HDAC3 expression. The gene discussed is HDAC3; the disease is non-small cell lung carcinoma.